This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hofbauer, G. F. Articles by Dummer, R. Search for Related Content PubMed PubMed Citation Articles by Hofbauer, G. F. Articles by Dummer, R.

American Journal of Pathology, Vol 151, 1549-1553, Copyright © 1997 by American Society for Investigative Pathology

REGULAR ARTICLES

MAGE-3 immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: frequency and distribution

GF Hofbauer, C Schaefer, C Noppen, R Boni, J Kamarashev, FO Nestle, GC Spagnoli and R Dummer
Department of Dermatology, University Hospital, Zurich, Switzerland.

Monoclonal antibody 57B specifically detects MAGE-3 gene protein expression. MAGE-derived peptides are recognized by CD8+ T cells and applied in immunotherapy. We examined formalin-fixed, paraffin-embedded tissue of 61 melanoma (primary, n = 40; metastatic, n = 21) and 46 control cases (junctional, dermal, compound, Spitz, Reed, and balloon- cell nevi) by immunohistochemistry using the alkaline phosphatase anti- alkaline phosphatase method after antigen retrieval. Immunoreactivity was rated positive at 20 positive cells per tumor or more. Staining pattern was homogeneous, scattered, or focal. All control samples and internal controls were immunonegative. Staining with monoclonal antibody 57B showed a specificity of 100% with a sensitivity of 44%. Immunopositivity (overall, 44% of melanomas) increased along with tumor, node, and metastasis stage; pT1 showed 13%, pT2 22%, pT3a 29%, pT3b 45%, pT4 100%, pTxN1 60%, and pTxNxM1a 63% of samples positive. The staining pattern was homogeneous on pT1 to pT3a tumors, homogeneous or focal in pT3b and pT4a, and homogeneous, focal, or scattered in pTxN1 and pTxNxM1a. The frequency of immunopositivity relates well to data on mRNA expression using reverse transcriptase polymerase chain reaction in a subgroup analyzed by both methods. Monoclonal antibody 57B can be used to allow profiling of melanomas using routine archival tissue, when considering immunotherapeutic approaches involving MAGE-3- derived epitopes.

This article has been cited by other articles:

				Y. Ueda, K. Shimizu, T. Itoh, N. Fuji, K. Naito, A. Shiozaki, Y. Yamamoto, T. Shimizu, A. Iwamoto, H. Tamai, et al. Induction of Peptide-Specific Immune Response in Patients with Primary Malignant Melanoma of the Esophagus after Immunotherapy Using Dendritic Cells Pulsed with MAGE Peptides Jpn. J. Clin. Oncol., February 1, 2007; 37(2): 140 - 145. [Abstract] [Full Text] [PDF]

				C. Barrow, J. Browning, D. MacGregor, I. D. Davis, S. Sturrock, A. A. Jungbluth, and J. Cebon Tumor Antigen Expression in Melanoma Varies According to Antigen and Stage Clin. Cancer Res., February 1, 2006; 12(3): 764 - 771. [Abstract] [Full Text] [PDF]

				A. Oberthuer, B. Hero, R. Spitz, F. Berthold, and M. Fischer The Tumor-Associated Antigen PRAME Is Universally Expressed in High-Stage Neuroblastoma and Associated with Poor Outcome Clin. Cancer Res., July 1, 2004; 10(13): 4307 - 4313. [Abstract] [Full Text] [PDF]

				E. Yakirevich, E. Sabo, O. Lavie, S. Mazareb, G. C. Spagnoli, and M. B. Resnick Expression of the MAGE-A4 and NY-ESO-1 Cancer-Testis Antigens in Serous Ovarian Neoplasms Clin. Cancer Res., December 15, 2003; 9(17): 6453 - 6460. [Abstract] [Full Text] [PDF]

				N. Sadanaga, H. Nagashima, K. Mashino, K. Tahara, H. Yamaguchi, M. Ohta, T. Fujie, F. Tanaka, H. Inoue, K. Takesako, et al. Dendritic Cell Vaccination with MAGE Peptide Is A Novel Therapeutic Approach for Gastrointestinal Carcinomas Clin. Cancer Res., August 1, 2001; 7(8): 2277 - 2284. [Abstract] [Full Text] [PDF]